MLTX 分类 A MoonLake Immunotherapeutics - Class A Ordinary Shares
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 10, 2026MLTX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
MLTX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
| 指标 | 5年趋势 | MLTX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -3.75年均值 ≈-30.3 | ≈-30.3 | · | · |
同行中位数按每项指标的标准化基础计算,可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | MLTX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| ROA | -50.4%5年均值 ≈-48.4% | ≈-48.4% | -40.4% | 弱 | |
| ROE | -60.5%5年均值 ≈-65.0% | ≈-65.0% | -46.3% | 弱 | |
| ROIC | -80.6%5年均值 ≈-82.0% | ≈-82.0% | -57.7% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | MLTX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 12.65年均值 ≈10.1 | ≈10.1 | 7.8 | 流动性强 | |
| Quick Ratio (速动比率) | 7.45年均值 ≈5.2 | ≈5.2 | 6.5 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
基本面数据不足,尚无法计算此比率组。
资本效率 资产周转率、库存周转率、应收账款周转率
基本面数据不足,尚无法计算此比率组。
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 12, 2026 | $-0.84 | $-0.94 | 10.4% |
| 2026年3月31日 | 五月 11, 2026 | $-0.98 | $-0.91 | -7.7% |
| 2025年12月31日 | $-0.92 | $-1.01 | 9.0% | |
| 2025年9月30日 | $-1.10 | $-0.90 | -22.8% | |
| 2025年6月30日 | $-0.87 | $-0.74 | -18.3% | |
| 2025年3月31日 | $-0.63 | $-0.77 | 17.9% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| R&D Expense | $203M | $113M | $32M | $42M | · | |
| SG&A Expense | $42M | $30M | $22M | $23M | $5M | |
| Operating Expenses | $245M | $143M | $54M | $65M | · | |
| Operating Income | $-245M | $-143M | $-54M | $-65M | $-5M | |
| Interest Income | · | · | · | · | $27.7K | |
| Other Non-op | · | · | · | $591.7K | $27.7K | |
| Pretax Income | $-230M | $-121M | $-44M | $-64M | · | |
| Income Tax | $611.0K | $282.0K | $94.0K | $36.4K | · | |
| Net Income | $-227M | $-119M | $-36M | $-50M | $-5M | |
| EPS (Basic) | $-3.53 | $-1.89 | $-0.73 | $-1.70 | · | |
| EPS (Diluted) | $-3.53 | $-1.89 | $-0.73 | $-1.70 | · | |
| Shares (Basic) | 64,463,889 | 62,870,237 | 49,122,534 | 29,361,353 | · | |
| Shares (Diluted) | 64,463,889 | 62,870,237 | 49,122,534 | 29,361,353 | 360,000,000 | |
| EBITDA | $-242M | $-142M | · | $-65M | $-5M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $335M | $180M | $451M | $40M | $8M | |
| Prepaid Expense | $23M | $23M | $2M | $4M | $1M | |
| Current Assets | $422M | $474M | $514M | $77M | $10M | |
| PP&E (Net) | $577.0K | $722.0K | $320.9K | $49.4K | $45.7K | |
| Other Non-current Assets | $596.0K | $0 | · | · | · | |
| Total Assets | $424M | $478M | $527M | $77M | $10M | |
| Accrued Liabilities | · | · | · | · | $4M | |
| Short-term Debt | · | · | · | $0 | $15M | |
| Current Liabilities | $45M | $22M | $10M | $8M | $21M | |
| Capital Leases | $374.0K | $1M | $2M | $129.0K | $0 | |
| Total Liabilities | $120M | $25M | $13M | $8M | $21M | |
| Long-term Debt | $74M | $0 | · | · | · | |
| Total Debt | · | · | · | $0 | · | |
| Common Stock | · | · | · | $0 | $38.5K | |
| Paid-in Capital | $767M | $677M | $610M | $129M | $42M | |
| Retained Earnings | $-463M | $-236M | $-117M | $-81M | $-54M | |
| Treasury Stock | · | · | · | $0 | $6.2K | |
| AOCI | $604.0K | $5M | $2M | $350.9K | $-168.2K | |
| Stockholders' Equity | $304M | $447M | $496M | $49M | $-12M | |
| Liabilities + Equity | $424M | $478M | $527M | $77M | $10M | |
| Shares Outstanding | · | · | · | · | 12,161,331 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| D&A | $3M | $1M | $370.0K | $164.8K | · | |
| Stock-based Comp | $13M | $7M | $7M | $10M | · | |
| Other Non-cash | $16M | $-6M | · | · | · | |
| Operating Cash Flow | $-196M | $-117M | $-43M | $-56M | $-611.1K | |
| CapEx | $35.0K | $520.0K | $284.0K | $16.0K | · | |
| Investing Cash Flow | $203M | $-206M | $-25M | $-32M | · | |
| Debt Issued | $73M | $0 | $0 | · | · | |
| Net Debt Issued | $73M | · | · | · | · | |
| Stock Repurchased | · | $50 | $0 | $0 | · | |
| Net Stock Activity | · | $-50 | · | · | · | |
| Financing Cash Flow | $146M | $51M | $480M | $120M | $-58.1K | |
| Net Change in Cash | $154M | $-271M | $412M | $31M | $-669.1K | |
| Taxes Paid | $799.0K | $147.0K | $42.0K | $4.3K | · | |
| Free Cash Flow | $-196M | $-117M | · | $-56M | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| ROA | -50.4% | -23.7% | · | -115.5% | -3.9% | |
| ROE | -60.5% | -25.2% | · | -268.3% | 94.1% | |
| ROIC | -80.6% | -32.1% | · | -133.1% | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 9.3 | 21.1 | · | 10.0 | 0.2 | |
| Quick Ratio | 7.4 | 8.0 | · | 5.2 | 0.2 | |
| Debt / Equity | · | · | · | 0.0 | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash Flow / Share | $-3.04 | $-1.85 | · | $-1.90 | $-0.00 | |
| EPS (TTM) | $-3.53 | $-1.89 | $-0.73 | $-1.70 | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Net Income TTM | $-227M | $-119M | $-36M | $-50M | $-5M | |
| P/E | -3.7 | -28.7 | -82.7 | -6.2 | · | |
| Earnings Yield | -26.8% | -3.5% | -1.2% | -16.2% | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $50M | $55M | $56M | $61M | $50M | $36M | $40M | $36M | $24M | $13M | $8M | $9M | $7M | $9M | $11M | $10M | |
| SG&A Expense | $11M | $16M | $9M | $11M | $11M | $11M | $9M | $7M | $7M | $7M | $5M | $4M | $6M | $6M | $6M | $5M | |
| Operating Expenses | $62M | $70M | $65M | $71M | $61M | $47M | $50M | $43M | $31M | $20M | $13M | $13M | $13M | $15M | $18M | $16M | |
| Operating Income | $-62M | $-70M | $-65M | $-71M | $-61M | $-47M | $-50M | $-43M | $-31M | $-20M | $-13M | $-13M | $-13M | $-15M | $-18M | $-16M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $657 | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $8.4K | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $842.7K | $723.6K | $37.6K | $245.1K | $69.5K | |
| Income Tax | $90.0K | $622.0K | $248.0K | $115.0K | $95.0K | $153.0K | $41.0K | $92.0K | $79.0K | $70.0K | $28.9K | $10.1K | $11.0K | $8.7K | $9.3K | $7.3K | |
| Net Income | $-62M | $-70M | $-62M | $-70M | $-55M | $-40M | $-46M | $-35M | $-24M | $-14M | $-9M | $-10M | $-9M | $-10M | $-12M | $-16M | |
| EPS (Basic) | $-0.84 | $-0.98 | $-0.93 | $-1.10 | $-0.87 | $-0.63 | $-0.72 | $-0.56 | $-0.39 | $-0.22 | $-0.18 | $-0.23 | $-0.23 | $-0.27 | $-0.34 | $-3.17 | |
| EPS (Diluted) | $-0.84 | $-0.98 | $-0.93 | $-1.10 | $-0.87 | $-0.63 | $-0.72 | $-0.56 | $-0.39 | $-0.22 | $-0.18 | $-0.23 | $-0.23 | $-0.27 | $-0.34 | $-3.17 | |
| Shares (Basic) | 73,915,296 | 71,273,650 | · | 63,369,984 | 63,282,728 | 63,233,788 | · | 62,896,782 | 62,874,637 | 62,637,212 | 53,517,655 | 43,718,464 | 39,061,977 | 36,925,639 | 35,201,713 | 5,013,646 | |
| Shares (Diluted) | 73,915,296 | 71,273,650 | · | 63,369,984 | 63,282,728 | 63,233,788 | · | 62,896,782 | 62,874,637 | 62,637,212 | 53,517,655 | 43,718,464 | 39,061,977 | 36,925,639 | 35,201,713 | 5,013,646 | |
| EBITDA | $-62M | $-69M | · | $-71M | $-61M | $-47M | · | $-43M | $-31M | $-20M | $-13M | $-13M | $-13M | $-15M | $-18M | $-3M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $478M | $298M | $335M | $351M | $307M | $272M | $180M | $376M | $343M | $458M | $318M | $502M | $50M | $41M | $93M | $23.3K | |
| Prepaid Expense | $26M | $33M | $23M | $27M | $27M | $23M | $23M | $16M | $15M | $5M | $3M | $4M | $3M | $4M | $5M | $135.9K | |
| Current Assets | $570M | $397M | $422M | $411M | $455M | $506M | $474M | $512M | $537M | $554M | $500M | $506M | $67M | $89M | $98M | $116M | |
| PP&E (Net) | $487.0K | $532.0K | $577.0K | $622.0K | $667.0K | $711.0K | $722.0K | $581.4K | $481.7K | $509.8K | $39.5K | $42.8K | $46.1K | $52.7K | $56.0K | · | |
| Other Non-current Assets | $1M | $1M | $596.0K | $587.0K | $2M | $2M | $0 | · | · | · | · | · | · | · | · | · | |
| Total Assets | $574M | $400M | $424M | $414M | $460M | $511M | $478M | $518M | $545M | $564M | $500M | $507M | $67M | $89M | $98M | $231M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $6M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $150.0K | |
| Current Liabilities | $45M | $46M | $45M | $48M | $27M | $24M | $22M | $20M | $12M | $9M | $10M | $7M | $7M | $6M | $4M | $203M | |
| Capital Leases | $772.0K | $865.0K | $374.0K | $486.0K | $836.0K | $1M | $1M | $2M | $2M | $2M | $13.1K | $53.0K | $91.1K | · | · | · | |
| Total Liabilities | $146M | $146M | $120M | $123M | $102M | $99M | $25M | $23M | $15M | $12M | $11M | $8M | $8M | $6M | $4M | $207M | |
| Long-term Debt | $100M | $99M | $74M | $74M | $73M | $73M | $0 | · | · | · | · | · | · | · | · | · | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $150.0K | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $385 | |
| Paid-in Capital | $1.02B | $786M | $767M | $689M | $684M | $681M | $677M | $675M | $672M | $670M | $531M | $590M | $131M | $124M | $122M | $34M | |
| Retained Earnings | $-594M | $-533M | $-463M | $-400M | $-331M | $-276M | $-236M | $-190M | $-155M | $-130M | $-109M | $-100M | $-90M | $-69M | $-59M | $-10M | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | |
| AOCI | $630.0K | $322.0K | $604.0K | $278.0K | $520.0K | $2M | $5M | $3M | $3M | $3M | $3M | $35.1K | $340.1K | $245.3K | $133.7K | · | |
| Stockholders' Equity | $428M | $254M | $304M | $289M | $354M | $408M | $447M | $488M | $521M | $543M | $425M | $490M | $42M | $55M | $64M | $24M | |
| Liabilities + Equity | $574M | $400M | $424M | $414M | $460M | $511M | $478M | $518M | $545M | $564M | $500M | $507M | $67M | $89M | $98M | $231M | |
| Shares Outstanding | · | · | · | · | · | · | · | · | · | · | · | · | · | 0 | 0 | · |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $896.0K | $845.0K | $751.0K | $745.0K | $742.0K | $378.0K | $364.0K | $351.0K | $342.0K | $328.0K | · | · | · | · | · | · | |
| Stock-based Comp | $3M | $13M | $4M | $4M | $3M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $3M | $3M | $2M | $2M | |
| Other Non-cash | · | $-11M | · | · | · | $-864.0K | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-56M | $-66M | $-59M | $-45M | $-55M | $-38M | $-48M | $-25M | $-28M | $-15M | $-9M | $-12M | $-9M | $-9M | $-34M | $-14M | |
| CapEx | $0 | $0 | $0 | $0 | $0 | $35.0K | $176.0K | $132.2K | $235 | $212.0K | $0 | $0 | $0 | $0 | $-2 | $16.0K | |
| Investing Cash Flow | $322.0K | $98.0K | $-30M | $88M | $88M | $56M | $-147M | $58M | $-88M | $-29M | $-174M | $13M | $20M | $-42M | $2 | $-16.0K | |
| Debt Issued | $0 | $24M | $0 | $0 | $0 | $73M | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Debt Issued | · | $24M | · | · | · | $73M | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $44M | $6M | · | $0 | $0 | $0 | · | $-190 | $-190 | $53M | $0 | $451M | $0 | $0 | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $50 | $0 | $0 | $0 | · | · | · | |
| Net Stock Activity | · | $6M | · | · | · | $0 | · | · | · | $53M | · | · | · | · | · | · | |
| Financing Cash Flow | $235M | $31M | $72M | $480.0K | $0 | $73M | $151.0K | $183.1K | $95 | $51M | $0 | $451M | $0 | $0 | $120M | $15M | |
| Net Change in Cash | $179M | $-36M | $-16M | $44M | $35M | $91M | $-195M | $33M | $-116M | $7M | $-184M | $452M | $11M | $-52M | $85M | $795.3K | |
| Taxes Paid | · | · | $733.0K | · | · | · | $143.0K | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-66M | · | · | · | $-38M | · | · | · | $-15M | · | · | $-9M | · | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -11.9% | -15.3% | · | -14.9% | -11.0% | -7.4% | · | -7.0% | -4.6% | -4.3% | -3.2% | -3.4% | -6.0% | -9.9% | -11.3% | -1.6% | |
| ROE | -15.8% | -21.1% | · | -17.9% | -12.6% | -8.4% | · | -7.8% | -4.8% | -4.7% | -3.9% | -3.7% | -27.1% | -40.1% | -35.4% | -18.4% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.6 | 8.6 | · | 8.5 | 16.6 | 21.1 | · | 25.5 | 43.7 | 62.1 | 48.5 | 71.0 | 9.1 | 14.7 | 25.5 | 0.6 | |
| Quick Ratio | 10.5 | 6.5 | · | 7.3 | 11.2 | 11.3 | · | 18.7 | 27.9 | 51.4 | 30.9 | 70.3 | 6.9 | 6.8 | 24.0 | 0.0 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -4127.1 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow / Share | · | $-0.93 | · | · | · | $-0.60 | · | · | · | $-0.24 | · | · | $-0.23 | · | · | · | |
| EPS (TTM) | $-3.85 | $-3.88 | · | $-3.32 | $-2.78 | $-2.30 | · | $-1.26 | $-0.88 | $-0.72 | $1.44 | $1.35 | $1.24 | · | · | · |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-264M | $-257M | · | $-210M | $-176M | $-145M | · | $-81M | $-55M | $-41M | $-40M | $-41M | $-43M | $-4M | $218.6K | $-20M | |
| Market Cap | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | $-41M | $-93M | · | |
| P/E | -5.1 | -4.8 | · | -2.2 | -17.0 | -17.0 | · | -40.0 | -50.0 | -69.8 | 39.6 | 37.8 | 17.2 | · | · | · | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | · | |
| Earnings Yield | -19.8% | -20.8% | · | -46.3% | -5.9% | -5.9% | · | -2.5% | -2.0% | -1.4% | 2.5% | 2.6% | 5.8% | · | · | · |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 净收入 | $-227M | $-119M | $-36M | $-50M | $-5M |
| 稀释后每股收益 (EPS) | $-3.53 | $-1.89 | $-0.73 | $-1.70 | · |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | · | · | · | 0.0 | · |
| 流动比率 | 9.3 | 21.1 | · | 10.0 | 0.2 |
| 速动比率 | 7.4 | 8.0 | · | 5.2 | 0.2 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-196M | $-117M | · | $-56M | · |
机构持有人 (13F) 195 家申报者 · $1.4B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 43 (-3 与上一季度对比) | 13 (-9 与上一季度对比) | 74 (+23 与上一季度对比) | 50 (+7 与上一季度对比) | +8.8M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BVF INC/IL | $311544999 | 16001284 | 22.99% | 股份 |
| Deep Track Capital, LP | $136271017 | 6999025 | 10.06% | 股份 |
| D. E. Shaw & Co., Inc. | $65526421 | 3365507 | 4.84% | 股份 |
| JANUS HENDERSON GROUP PLC | $64303830 | 3451628 | 4.75% | 股份 |
| Cormorant Asset Management, LP | $62409781 | 3205433 | 4.61% | 股份 |
| Logos Global Management LP | $52082250 | 2675000 | 3.84% | 股份 |
| Weiss Asset Management LP | $50267899 | 2581813 | 3.71% | 股份 |
| CITADEL ADVISORS LLC | $38412227 | 1972893 | 2.83% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $33397845 | 1715349 | 2.46% | 股份 |
| MPM BIOIMPACT LLC | $31287647 | 1606967 | 2.31% | 股份 |
| JPMORGAN CHASE & CO | $27603662 | 1386422 | 2.04% | 股份 |
| Vivo Capital, LLC | $27258000 | 1400000 | 2.01% | 股份 |
| Point72 Asset Management, L.P. | $22560512 | 1158732 | 1.66% | 股份 |
| BlackRock, Inc. | $21315581 | 1094791 | 1.57% | 股份 |
| Balyasny Asset Management L.P. | $17770561 | 912715 | 1.31% | 股份 |
| GREAT POINT PARTNERS LLC | $16662679 | 855813 | 1.23% | 股份 |
| JANE STREET GROUP, LLC | $16615426 | 853386 | 1.23% | 股份 |
| Candriam S.C.A. | $14972924 | 769766 | 1.10% | 股份 |
| BANK OF AMERICA CORP /DE/ | $14639435 | 751897 | 1.08% | 股份 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $14617628 | 750777 | 1.08% | 股份 |
| Trails Edge Capital Partners, LP | $14602500 | 750000 | 1.08% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $12524428 | 643268 | 0.92% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $12386561 | 636187 | 0.91% | 股份 |
| MORGAN STANLEY | $10973331 | 563602 | 0.81% | 股份 |
| MARSHALL WACE, LLP | $10715334 | 550351 | 0.79% | 股份 |
| Qube Research & Technologies Ltd | $9661832 | 496242 | 0.71% | 股份 |
| ALGERT GLOBAL LLC | $7534111 | 386960 | 0.56% | 股份 |
| Rhenman & Partners Asset Management AB | $7492056 | 384800 | 0.55% | 股份 |
| Trexquant Investment LP | $7358609 | 377946 | 0.54% | 股份 |
| Capricorn Fund Managers Ltd | $7294892 | 374866 | 0.54% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $6987471 | 358884 | 0.52% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $6649725 | 341537 | 0.49% | 股份 |
| Jump Financial, LLC | $6546652 | 336243 | 0.48% | 股份 |
| UBS Group AG | $6396323 | 328522 | 0.47% | 股份 |
| Caption Management, LLC | $6364743 | 326900 | 0.47% | 买入期权 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $6249870 | 321000 | 0.46% | 买入期权 |
| Granahan Investment Management, LLC | $6111321 | 313884 | 0.45% | 股份 |
| Boxer Capital Management, LLC | $5354250 | 275000 | 0.40% | 股份 |
| JANE STREET GROUP, LLC | $5334780 | 274000 | 0.39% | 买入期权 |
| CITADEL ADVISORS LLC | $5317257 | 273100 | 0.39% | 买入期权 |
| Susquehanna Portfolio Strategies, LLC | $4944874 | 253974 | 0.36% | 股份 |
| Holocene Advisors, LP | $4867500 | 250000 | 0.36% | 股份 |
| Burkehill Global Management, LP | $4867500 | 250000 | 0.36% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $4823537 | 247742 | 0.36% | 股份 |
| Walleye Capital LLC | $4806539 | 246869 | 0.35% | 股份 |
| J. Goldman & Co LP | $4204449 | 215945 | 0.31% | 股份 |
| Y-Intercept (Hong Kong) Ltd | $4202580 | 215849 | 0.31% | 股份 |
| ACUTA CAPITAL PARTNERS, LLC | $4198744 | 215652 | 0.31% | 股份 |
| CITADEL ADVISORS LLC | $4123746 | 211800 | 0.30% | 卖出期权 |
| Verition Fund Management LLC | $4032276 | 207102 | 0.30% | 股份 |
激进投资者及 5%+ 股东 2 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF PARTNERS L P/IL, BVF INC/IL, LAMPERT MARK N, Loy Spike ×3 申报 | 2026年6月29日 | 19.70% | 修订 | · | SEC |
| BIOTECHNOLOGY VALUE FUND, L.P., BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II, L.P., BVF II GP LLC, BIOTECHNOLOGY VALUE TRADING FUND OS, L.P., BVF PARTNERS OS LTD., BVF GP HOLDINGS LLC, BVF PARTNERS L.P., BVF INC., MARK N. LAMPERT, SPIKE LOY ×4 申报 | 2024年10月8日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 10 位内幕人士 · 3 位高管 · 6 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Da Silva Jorge Santos | Chief Executive Officer | 2026年7月10日 S | 2774893 | 0 | 7 | $-8730001 |
| Matthias Bodenstedt | Chief Financial Officer | 2026年6月22日 S | 1115435 | 1 | 7 | $-3099694 |
| Kristian Reich | Chief Scientific Officer | 2026年7月27日 S | 2711198 | 0 | 10 | $-8135616 |
| Andrew John Phillips | 董事 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Ramnik Xavier | 董事 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Loy Spike | 董事 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Catherine Moukheibir | 董事 | 2026年6月17日 A | 0 | 0 | 0 | $0 |
| Simon Sturge | 董事 | 2025年6月5日 A | 171980 | 0 | 0 | $0 |
| Chen Bihua | 10% 所有者 | 2023年6月30日 P | 4927100 | 0 | 0 | $0 |
| Helix Holdings LLC | · | 2022年4月5日 C | 3215000 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
ETF持仓 由 6 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.66% | 16630 NS | 2026年7月31日 | N-PORT |
| NUSC · Nushares ETF Trust | 0.05% | 34135 NS | 2026年7月31日 | N-PORT |
| ESML · iShares Trust | 0.04% | 87790 SH | 2026年9月11日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 20634 NS | 2026年7月31日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.01% | 130327 SH | 2026年8月19日 | 每日 |
| WSML · iShares Trust | 0.01% | 3137 SH | 2026年9月11日 | 每日 |
MLTX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
12个月价格目标
13 位分析师 · 2026-09-27平均目标 $28.54 +150.1%
同行比较(GICS 子行业) 关键指标与行业同行对比
财年依据,价格截至各公司上一个财年末收盘价。
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存,并会跟随您浏览所有股票。